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Abstract
Objectives: Matrix metalloproteinase-8 (MMP-8) promotes lung fibrotic responses to bleomycin in mice. Although prior
studies reported that MMP-8 levels are increased in plasma and bronchoalveolar lavage fluid (BALF) samples from IPF
patients, neither the bioactive forms nor the cellular sources of MMP-8 in idiopathic pulmonary fibrosis (IPF) patients have
been identified. It is not known whether MMP-8 expression is dys-regulated in IPF leukocytes or whether MMP-8 plasma
levels correlate with IPF outcomes. Our goal was to address these knowledge gaps.
Methods: We measured MMP-8 levels and forms in blood and lung samples from IPF patients versus controls using ELISAs,
western blotting, and qPCR, and assessed whether MMP-8 plasma levels in 73 IPF patients correlate with rate of lung
function decline and mortality. We used immunostaining to localize MMP-8 expression in IPF lungs. We quantified MMP-8
levels and forms in blood leukocytes from IPF patients versus controls.
Results: IPF patients have increased BALF, whole lung, and plasma levels of soluble MMP-8 protein. Active MMP-8 is the
main form elevated in IPF lungs. MMP-8 mRNA levels are increased in monocytes from IPF patients, but IPF patients and
controls have similar levels of MMP-8 in PMNs. Surprisingly, macrophages and airway epithelial cells are the main cells
expressing MMP-8 in IPF lungs. Plasma and BALF MMP-8 levels do not correlate with decline in lung function and/or
mortality in IPF patients.
Conclusion: Blood and lung MMP-8 levels are increased in IPF patients. Active MMP-8 is the main form elevated in IPF lungs.
Surprisingly, blood monocytes, lung macrophages, and airway epithelial cells are the main cells in which MMP-8 is
upregulated in IPF patients. Plasma and BALF MMP-8 levels are unlikely to serve as a prognostic biomarker for IPF patients.
These results provide new information about the expression patterns of MMP-8 in IPF patients.
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Introduction
IPF is associated with high morbidity and mortality [1] and its
incidence is increasing [2,3]. No therapies have been shown to
reduce mortality in IPF patients [4–6]. IPF is thought to be caused
by an initial (as-yet unidentified) alveolar epithelial injury which is
followed by an aberrant wound healing response in the lung [7,8],
but the pathways that contribute to this response are not fully
understood. An improved understanding of the mechanisms
involved in the pathogenesis of IPF may facilitate the development
of more efficacious therapeutic approaches for this disease.
One molecule that has recently been linked to fibrotic lung
diseases is matrix metalloproteinase-8 (MMP-8 or neutrophil
collagenase). MMP-8 degrades type I collagen (the major collagen
deposited in IPF lungs) in vitro [9]. However, recent studies have
shown that MMP-8 promotes (rather than inhibits) lung fibrosis in
bleomycin-treated mice, and this is linked to MMP-8’s activities in
reducing lung levels of macrophage inflammatory protein 1a
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e97485(MIP-1a) and interferon-inducible protein-10 (IP-10) which is an
anti-fibrotic cytokine [10–12].
MMP-8 is most highly expressed by neutrophils [13]. However,
macrophages stimulated ex vivo with CD40 ligand [14] and
activated fibroblasts [10,15,16] also express MMP-8 albeit at lower
levels than neutrophils. All MMP-8-expressing cells release a
soluble form of MMP-8 as a latent (pro)-proteinase which is then
activated in the extracellular space. Activated neutrophils also
express another form of MMP-8 on their surface in an inducible
fashion [12,17]. Membrane-bound MMP-8 on PMNs is catalyt-
ically active but resistant to inhibition by tissue inhibitors of
metalloproteinases and could be the key form mediating its
activities in vivo [12,17]. However, membrane-bound MMP-8 on
PMNs has not been studied in any human disease.
A small number of prior studies have linked MMP-8 to human
IPF. One study reported that MMP-8 plasma levels are elevated in
IPF patients [18], but this study did not assess whether plasma
MMP-8 levels correlate with clinical outcomes or parameters in
IPF patients. One study reported that MMP-8 expression was not
increased in IPF whole lung samples [19]. Several other studies
showed that IPF patients have elevated levels of soluble MMP-8 in
bronchoalveolar lavage fluid (BALF) [18,20–22]. One of these
studies showed, in a small cohort of IPF subjects, that elevated
MMP-8 BALF levels are associated with rapidly declining lung
function [21].
Knowledge gaps in the area of MMP-8 and IPF include: 1)
which cells in the lung contribute to the elevated BALF MMP-8
levels in IPF patients; 2) whether MMP-8 levels in blood myeloid
leukocytes are dysregulated in IPF patients; 3) which is the key
form of the proteinase (soluble vs. membrane bound and active vs.
latent MMP-8) present in IPF blood and lung samples; and 4)
whether substrates that we have identified for MMP-8 in the
fibrotic murine lung are also potential substrates for MMP-8 in
human IPF lungs. To address these knowledge gaps, we performed
a comprehensive analysis of MMP-8 levels and forms in both
blood and lung samples from IPF patients versus control subjects.
We measured levels of substrates that we have identified for MMP-
8 in the fibrotic murine lung (MIP-1a and IP-10) in IPF lung
samples to begin to assess whether they might be substrates for
MMP-8 in IPF lungs. We also assessed whether plasma MMP-8
levels can serve as a prognostic biomarker for IPF.
Based upon current knowledge of MMP-8 expression patterns,
we hypothesized that MMP-8 is mainly expressed by neutrophils
and fibroblasts in IPF lungs. As there is evidence that blood
neutrophils are activated and undergo degranulation in IPF
patients [23], we also hypothesized that MMP-8 levels would be
lower in extracts of blood neutrophils and/or higher on the surface
of blood neutrophils from IPF patients compared with controls.
However, we report for the first time that lung macrophages and
airway epithelial cells are the key sources of MMP-8 in IPF lungs.
Although we confirmed that plasma MMP-8 levels are increased
in IPF patients, surprisingly, MMP-8 levels are not altered in
neutrophils from IPF patients. Rather, IPF patients have increased
expression of MMP-8 in blood monocytes. Thus, we provide new
information about expression and activation patterns of MMP-8 in
IPF lung samples which may guide future biomarker studies, and
possibly the testing of novel therapeutics targeting MMP-8 for IPF.
Materials and Methods
Human subjects
All research involving human participants was approved by the
authors’ institutional review board [The Partners Health Care
Institutional Review Board (IRB) under protocols #2011P002419
and 2002P000253]. All study subjects signed written informed
consent forms that were approved by our IRB. All clinical
investigations were conducted according to the principles
expressed in the Declaration of Helsinki.
Blood or BALF samples were obtained from healthy volunteers
(n=25 or 12, respectively) and IPF patients (n=73 or 32,
respectively) enrolled in the Brigham and Women’s Hospital
Interstitial Lung Disease Registry or who signed informed consent
and were enrolled in NIH protocols (99-HG-0056 and 04-HG-
0211). The diagnosis of IPF was made using ATS/ERS consensus
diagnostic criteria [24]. Forced vital capacity (FVC) and diffusing
capacity of the lung for carbon monoxide (DLCO)] were recorded
on IPF patients for clinical indications. Explanted lung samples
from IPF patients undergoing lung transplantation and controls
(rejected donor lung transplant tissue) were randomly selected
from our IPF bio-repository.
MMP-8, MIP-1a, and IP-10 levels
MMP-8 was quantified in blood and lung samples using an
ELISA (R&D Systems, Minneapolis, MN). MMP-8 levels in
homogenates of lung samples were corrected for GAPDH levels
which were measured in arbitrary units using a commercial kit
(eBioscience, San Diego, CA). MMP-8 results were expressed as pg
of MMP-8 per arbitrary unit of GAPDH. MIP-1a and IP-10 were
quantified in BALF samples using ELISAs (PeproTech, Rocky
Hill, NJ). MMP-8 forms were analyzed in BALF (50 microliters/
sample) and lung lysates (100 micrograms of protein/sample) using
western blotting [12,17] and a polyclonal rabbit anti-human
MMP-8 IgG [ab38994; raised against the hinge region of MMP-8
(Abcam, Cambridge, MA)] and quantified using ImageJ software
[25].
Leukocyte studies
Neutrophils and monocytes were isolated from blood using
density gradient centrifugation [26] and positive selection for
CD14 using immuno-magnetic beads (Miltenyi Biotec, San Diego,
CA), respectively. Cells were lysed in radio-immunoprecipitation
assay (RIPA) buffer containing protease inhibitors (at 5610
6 cells/
ml), and frozen at 280uC. Intact neutrophils were immunostained
for surface MMP-8 using Alexa 488 and rabbit anti-MMP-8 IgG
(ab38994, Abcam) or non-immune rabbit IgG as a control (Dako,
Carpinteria, CA) [12,17] and staining quantified using a FACS
Canto II flow cytometer (BD, Franklin Lakes, NJ).
Real-time RT-PCR
Real-time RT-PCR was performed on RNA isolated from
blood leukocytes and lungs using a MMP-8 gene expression assay
(Invitrogen, Eugene, OR), and the comparative cycle threshold
method with 18S as an endogenous reference gene [10].
Immunoperoxidase staining
Formalin-fixed lung sections from IPF patients and control
subjects were deparaffinized. Antigen retrieval was performed by
boiling the sections in 10 mM citrate buffer (pH 6.0) in a
microwave for 10 min. Slides were incubated in blocking buffer
[1% (w/v) BSA and 10% (v/v) goat serum in Tris buffered saline
(TBS; 0.05M Tris containing 0.15 M NaCl and 0.02 M CaCl2]
for 2 h at room temperature. Slides were then incubated with
either rabbit anti-MMP-8 IgG or non-immune rabbit IgG for 18 h
at 4uC and washed twice in TBS. Slides were incubated in 3%
hydrogen peroxide solution for 20 min, washed, incubated again
with hydrogen peroxide solution, washed, and incubated for 1 h at
room temperature with goat anti-rabbit IgG conjugated to
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were washed, incubated in avidin-biotin complex for 1 h at room
temperature, washed again, and developed using 3,39-diamino-
benzidine. Slides were then counterstained with 1% (wt/vol)
methyl green solution, dehydrated, and mounted.
Immunofluorescence staining to localize MMP-8 in lung
sections
Formalin-fixed lung sections from IPF patients and controls
were deparaffinized, and antigen retrieval was performed by
heating the slides in a microwave in citrate buffer, as outlined
above. The sections were incubated overnight at 4uC with rabbit
IgG to human MMP-8 (or non-immune rabbit IgG) and Alexa
546-conjugated goat anti-rabbit F(ab)2. Sections were then washed
in PBS and incubated at 37uC for 2 h with either murine anti-
CD68 IgG (Dako, Carpinteria, CA), murine anti-vimentin IgG
(Abcam), murine anti-surfactant protein C IgG (SP-C, Santa Cruz
Biotechnology, Santa Cruz, CA.), murine anti-pancytokeratin IgG
(Sigma-Aldrich, St. Louis, MO), or non-immune murine IgG [27].
After washing the lung sections in PBS, Alexa 488-conjugated goat
anti-murine F(ab)2 was applied and slides were incubated for
additional 1 h at 37uC. Nuclei were then counterstained with 49,6-
diamidino-2-phenylindole (DAPI).
Immunostaining to detect apoptosis of alveolar type II
epithelial cells in lung sections
To detect the alveolar epithelial type II (ATII) cells undergoing
apoptosis, we performed double immunofluorescence staining of
lung sections for active (cleaved) caspase-3 and a marker of ATII
cells (surfactant protein C; SP-C). Formalin-fixed lung sections
from IPF patients and controls were deparaffinized, and antigen
retrieval was performed by heating the slides in a microwave in
citrate buffer. The sections were incubated overnight at 4uC with
murine anti-active caspase-3 IgG (Abcam, Cambridge, MA), or
non-immune murine IgG (Sigma-Aldrich, St. Louis MO) followed
by Alexa 488-conjugated goat anti-murine F(ab)2. Slides were
washed in PBS and incubated with goat anti-SP-C IgG (Santa
Cruz Biotechnology, Santa Cruz, CA.) or non-immune goat IgG
(Sigma-Aldrich, St. Louis, MO) followed Alexa 546-conjugated
rabbit anti-goat F(ab)2. Nuclei were counterstained with DAPI.
Statistics
The results for paired and unpaired data were compared using
the Student’s t-test for parametric data and the Mann-Whitney
rank sum test for non-parametric data; P values less than 0.05 were
considered significant. To study associations between MMP-8
plasma levels and FVC or DLCO and, results from patients with
$2 clinic visits were analyzed and FVC and DLCO results from
the second and third visits were expressed as a % of baseline
values. Linear regression was performed for each patient and the
slope was used to calculate the annual percent change in relative
and absolute FVC and DLCO, and Spearman Rank Correlation
Coefficients for non-parametric data were calculated. The Cox
proportional-hazards regression model was used to determine
whether there is a relationship between plasma MMP-8 levels and
survival in IPF patients.
Results
MMP-8 levels in IPF lungs
Soluble MMP-8 protein levels are ,5-fold higher in BALF from
IPF patients compared with healthy volunteers (Fig. 1A and Table
S1 for demographic data on the subjects). Two main forms of
MMP-8 are detected in BALF using Western blotting (Fig. 1B): 1)
active MMP-8 (Mr,60 kDa) which is the most abundant form;
and 2) a ,40 kDa form which likely is a proteolytically processed
and inactive form of MMP-8 (containing its hinge region and the
hemopexin MMP-8 domains) which we have detected in BALF
from mice with acute lung injury [12]. Both forms are increased in
IPF BALF (Figs. 1C and 1D). Latent pro-MMP-8 (Mr,80 kDa) is
not detected or present at only low levels in BALF samples from
IPF cases and controls. MMP-8 protein levels are also strikingly
increased in homogenates of lung samples from IPF patients
(Fig. 2A), but whole lung MMP-8 steady-state mRNA levels are
similar in IPF patients and control subjects (Fig. 2B).
MMP-8 localization in IPF lungs
Based upon current knowledge of MMP-8 expression patterns,
we hypothesized that MMP-8 is mainly expressed by PMNs and
fibroblasts in IPF lungs. To test this hypothesis, we first performed
immunoperoxidase staining of lung sections for MMP-8. There is
robust staining for MMP-8 in bronchial epithelial cells in areas of
moderately severe and severe fibrosis in IPF lungs. However, there
is minimal or no staining for MMP-8 in areas of mild fibrosis in
IPF lung and in rejected normal lung transplant donor lungs
(Fig. 3A). In addition, positive staining for MMP-8 is present in
cells in fibrotic lung tissue but not in control lung tissue (Fig. 3B),
and no staining in IPF lung stained with a non-immune control
primary antibody (Fig. 3A, right panel).
To confirm these results and identify the cell types in which
MMP-8 is regulated in IPF lungs, we double immuno-stained lung
sections from explanted IPF lungs and rejected normal lung
transplant donor lungs using a green fluorophore for MMP-8 and
a red fluorophore for markers of epithelial cells, macrophages,
neutrophils, or fibroblasts. Macrophages are strongly stained for
MMP-8 in all areas of the lung including areas of mild and severe
fibrosis in IPF lung tissue (Fig. 4 upper panel). However,
macrophages are not stained for MMP-8 in control lung samples
(Fig. 4 lower panel). Bronchial epithelial cells in IPF lung tissue
(Fig. 4, upper panel) are positively stained for MMP-8 mainly in
areas of severe lung fibrosis (Fig. 4 upper panel). However, in
control lung tissue, bronchial epithelial cells stain only weakly for
MMP-8 (Fig. 4, lower panel). The few neutrophils present in IPF
lungs stain strongly for MMP-8 (Fig. 4 upper panel). Fibroblasts
(Fig. 5, upper panel) and fibrobastic foci (not shown) in IPF lung
are not stained for MMP-8. Type II alveolar epithelial (ATII) cells
stain strongly for MMP-8 in control lung tissue (Fig. 5, lower
panel) but there is minimal or no staining for MMP-8 in these cells
in areas of moderately severe and severe fibrosis in IPF lungs
(Fig. 5). Staining for MMP-8 in ATII cells in areas of mild fibrosis
in IPF lung is similar to that in normal lungs (data not shown).
There is no staining in lung sections from IPF patients (Fig. 5) or
control subjects (data not shown) incubated with isotype-matched
non-immune control antibodies, confirming that our staining for
MMP-8 and markers of different cell types is specific.
To determine whether the reduced MMP-8 staining in ATII
cells in IPF lungs is linked to increased rates of ATII cell apoptosis
which has been reported in IPF lungs [28,29], we double
immunostained IPF versus normal lungs for a marker of apoptosis
(active caspase-3) and a marker of ATII cells (surfactant protein C;
SP-C). Positive immunostaining for active caspase-3 is present in
areas of moderately severe and severe fibrosis in IPF lung
parenchyma but not in normal lung parenchyma (Fig. 6).
However, the apoptotic cells in IPF lung parenchyma are not
ATII cells as there is minimal or no co-localization of the staining
for active caspase-3 and SP-C.
Novel Cellular Sources of MMP-8 in IPF Patients
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Plasma MMP-8 protein levels are .3–fold higher in IPF
patients when compared with levels in healthy volunteers (Fig. 7).
Table 1 shows the demographic data on these subjects.
MMP-8 levels in blood neutrophils
As there is evidence that blood neutrophils are activated in IPF
patients [23], we hypothesized that MMP-8 protein levels are
lower in extracts of blood neutrophils but higher on the surface of
blood neutrophils from IPF patients compared with levels in
control subjects. However, we show that MMP-8 protein levels are
similar in blood neutrophil extracts from IPF patients and control
subjects (Fig. 8A). The percentage of neutrophils that stain
positively for surface MMP-8 (which increases when neutrophils
are activated [12,17]) is also similar in IPF patients and controls
(17.86 SEM 5.6%; n=32 versus 3.461.9%; n=5, respectively;
Figure 1. MMP-8 protein levels are increased in IPF BALF samples. In A, BAL was performed on IPF patients (n=32) and healthy volunteers
(n=7), and MMP-8 protein levels were quantified in BAL fluid (BALF) samples using an ELISA. Data are mean + SEM; * indicates p=0.003. In B,w e
analyzed BALF samples from both groups using Western blotting, and detected both active MMP-8 protein (,60 kDa) and processed MMP-8
(,40 kDa) forms in BALF from IPF patients and healthy volunteers. B shows a representative blot of BALF samples from 5 IPF patients and 4 control
subjects. In C–D, densitometry was used to quantify levels of active MMP-8 (in C) and processed MMP-8 (in D) in BALF samples. In C and D, data are
mean + SEM; n=9 control samples and n=9 IPF samples; asterisk indicates p=0.022 and ** p=0.002.
doi:10.1371/journal.pone.0097485.g001
Figure 2. MMP-8 protein levels are increased in IPF whole lung samples. Lung tissue was removed from explanted lungs from IPF patients
during lung transplantation (n=5) or unused transplant donor lungs (control; n=5). In A, MMP-8 protein levels were measured in homogenates of
lung samples using an ELISA. Results for MMP-8 were normalized to GAPDH levels (expressed as pg of MMP-8 per arbitrary unit of GAPDH). Data are
mean + SEM. Asterisk indicates p,0.03. In B, MMP-8 steady-state mRNA levels were measured in RNA isolated from whole lung samples. Data are fold
change + SEM; n=5 control subjects and 4 IPF patients.
doi:10.1371/journal.pone.0097485.g002
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mRNA level in blood PMNs. However, we detected MMP-8
transcripts in PMNs from healthy donors using qRT-RT-PCR.
IPF patients and controls have similar low levels of MMP-8
mRNA transcripts in blood neutrophils (Fig. 8B).
MMP-8 levels in blood monocytes
In healthy donors, blood monocyte extracts contain less MMP-8
(,1 ng/5 million cells) than neutrophil extracts (,1000 ng/5
million cells) as expected (Figs. 8C and 8A, respectively). MMP-8
protein levels are similar in blood monocyte extracts from IPF
patients and control subjects (Fig. 8C). In blood monocytes, MMP-
8 mRNA levels are very low or not detectable in normal volunteers
(cycle threshold [CT] .60 cycles for 7 out of 9 healthy volunteers
and $25.3 in 2 healthy volunteers) whereas the CT for the IPF
patients ranges from 5.16 to 22.11. Thus, it is not possible to
calculate fold change in monocyte MMP-8 steady state mRNA
levels for IPF patents versus healthy subjects using the DDCT
method. Instead, we report MMP-8 steady state mRNA levels
using the DCT method for IPF patients versus controls (CT for
MMP-8 - CT for 18 S as the housekeeping gene). The lower DCT
for IPF patients indicates higher MMP-8 mRNA levels in
monocytes from IPF patients compared with control subjects
(Fig. 8D). We used publicly-available microarray gene expression
databases to compare MMP-8 expression in peripheral blood
mononuclear cells (PBMCs) from COPD versus healthy control
subjects [30] and sarcoidosis patients versus healthy control
subjects [31]. Our analysis shows that MMP-8 transcripts are
not detected in COPD PBMCs and MMP-8 expression is not
significantly increased in PBMCs from patients with sarcoidosis
(Table S2).
BALF MIP-1a and IP-10 levels
MMP-8 reduces lung levels of MIP-1a and IP-10 in bleomycin-
treated mice to promote pulmonary fibrosis [10–12]. However,
BALF levels of MIP-1a and IP-10 are not significantly different in
IPF patients and control subjects, and there are trends towards
higher (rather than lower) levels of both mediators in IPF patients
(Table S3). Among the IPF patients, BALF MMP-8 levels do not
correlate significantly with BALF levels of either MIP-1a or IP-10
(Spearman Rank Correlation Coefficients = 0.07 [p=0.84] and
0.31 [p=0.29], respectively).
MMP-8 levels in plasma, BALF, and PBMCs and clinical
outcomes
MMP-8 plasma levels do not significantly correlate with the
annual absolute rate of decline in FVC (Fig. 9A) or DLCO (Fig. 9B)
expressed as a percentage of the patients’ baseline FVC or DLCO,
or absolute FVC and DLCO (data not shown). In addition, plasma
MMP-8 levels do not correlate with initial FVC or DLCO at
presentation (data not shown). Plasma MMP-8 levels in 66 IPF
patients also do not correlate with mortality as assessed using the
Cox proportional-hazards model analysis (data not shown).
MMP-8 protein levels in BALF from IPF patients (n=32) do
not correlate with annual absolute rate of decline in FVC or
DLCO (data not shown). An analysis of a publicly-available
PBMC microarray gene expression dataset on IPF patients [32]
Figure 3. Immunostaining for MMP-8 is increased in IPF lungs.
Lung tissue was obtained from IPF patients undergoing lung
transplantation and unused transplant donor lungs (control). Immuno-
peroxidase staining for MMP-8 was performed on formalin-fixed IPF and
control lung sections. In A, there is positive (brown) staining for MMP-8
in bronchial epithelial cells in an area of severe fibrosis in the IPF lung
but not in bronchial epithelial cells in the control lung section. B shows
positive (brown) staining for MMP-8 in cells in fibrotic parenchyma in
IPF lungs (indicated by the arrows) but not in control lung parenchyma.
Lung sections stained with a non-immune rabbit IgG control primary
antibody (Rb IgG) showed minimal staining. These results are
representative of 3 different lung sections per group. Magnification is
X 400.
doi:10.1371/journal.pone.0097485.g003
Figure 4. MMP-8 expression is increased in macrophages and
bronchial epithelial cells in IPF lungs. Double immunofluorescence
staining of an IPF lung section (upper panels) and a control lung section
(lower panels) was performed using a red fluorophore (left column) for
macrophages (CD68), airway epithelial cells (pancytokeratin; PanCK), or
neutrophils (myeloperoxidase; MPO) and with a green fluorophore for
MMP-8 (middle column). Lung sections were also stained with isotype-
matched non-immune murine and rabbit IgG control antibodies (see
Fig. 5). Nuclei were stained with 49,6-diamidino-2-phenylindole (DAPI),
and lung sections were examined using a confocal microscope. Merged
images (right column) show co-localization of staining for MMP-8 and
CD68 and also for MMP-8 and PanCK in the bronchial epithelium of an
area of severe fibrosis in the IPF lung (upper panels). The control lung
section (lower panels) shows no staining for MMP-8 in macrophages
and minimal staining for MMP-8 (middle column) in bronchial epithelial
cells. Images are representative of immuno-stained lung sections from 2
controls and 3 patients with IPF. Magnification is X 600 in both panels.
doi:10.1371/journal.pone.0097485.g004
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levels do not correlate with mortality (personal communication,
Naftali Kaminski, MD, Yale University School of Medicine).
Discussion
MMP-8 has been identified as a pro-fibrotic proteinase in the
lungs of bleomycin-treated mice [10,11] but much less is known
about its roles in human IPF. Herein, we report that MMP-8
plasma levels are higher in IPF patients compared with control
subjects in agreement with results reported in one prior study [18].
However, we add to this literature by showing that MMP-8 plasma
levels do not correlate with annual rate of decline in lung function
or mortality in IPF patients. We hypothesized that MMP-8 levels
in blood neutrophils would be altered in IPF patients, as MMP-8 is
most highly expressed by neutrophils, and another study reported
that blood neutrophils are activated in IPF patients as indicated by
increased plasma neutrophil elastase levels in IPF patients [23].
Surprisingly, we found no differences in total cellular or surface
levels of MMP-8 in/on blood neutrophils from IPF patients when
compared with cellular levels in control subjects. We report for the
first time that MMP-8 gene expression levels are robustly
upregulated in blood monocytes in IPF patients, but MMP-8
gene expression in PBMCs does not correlate with mortality in IPF
patients when a publicly-available microarray dataset is analyzed.
Consistent with results from prior studies [18,20,21], MMP-8
protein levels are increased in BALF samples from our IPF cohort
but do not correlate with pulmonary function. Thus, BALF MMP-
8 levels are unlikely to serve as a useful prognostic biomarker for
IPF. However, our results add to the literature by showing that the
main form of MMP-8 that is increased in IPF BALF is active
MMP-8. Although we expected that neutrophils and fibroblasts
would express MMP-8 in IPF lungs, our study shows for the first
time that lung macrophages and bronchial epithelial cells are the
main sources of MMP-8 in IPF lungs. MMP-8 expressed by
macrophages and bronchial epithelial cells may contribute to the
fibrotic process in IPF lungs.
Until now, MMP-8 has not been well studied in blood samples,
Figure 5. MMP-8 is not expressed in type II alveolar epithelial
cells or fibroblasts in IPF lungs. Lung tissue was obtained from IPF
patients undergoing lung transplantation (upper panel) or from
rejected transplant donor lungs as a control (lower panel). Formalin-
fixed lung sections were stained with a red fluorophore (left column) for
fibroblasts (vimentin; VIM) or type II alveolar epithelial cells (surfactant
protein C, SPC) and a green fluorophore for MMP-8 (middle column).
Other lung sections were stained with isotype-matched non-immune
murine IgG (Ms IgG) or rabbit IgG (Rb IgG). Nuclei were stained with
DAPI and lung sections examined using a confocal microscope. Merged
images (right column) show no staining for MMP-8 in cells identified as
fibroblasts or type II alveolar epithelial (ATII) cells in an area of severe
fibrosis in the IPF lung. Control lung sections show positive staining for
MMP-8 in type II alveolar epithelial cells (lower panels). Magnification is
X 600.
doi:10.1371/journal.pone.0097485.g005
Figure 6. The lack of MMP-8 staining in type II alveolar
epithelial cells in IPF lungs is not due to increased rates of
apoptosis of these cells. Lung sections from a control and IPF
patient were stained with a red fluorophore for a marker of type II
alveolar epithelial cells (SP-C, left column) and with a green fluorophore
for active caspase-3 (Casp3; middle column as a marker of apoptotic
cells). Merged images (right) show apoptotic cells (stained green) in an
area of severe fibrosis in the IPF lung, but these apoptotic cells are not
ATII cells as assessed by the lack of co-localization of active caspase-3
and SP-C staining. There is no apoptosis in alveolar epithelial cells in the
control lung, as expected. The images are representative of immuno-
stained lung sections from 2 control subjects and 3 patients with IPF.
Magnification is X 600.
doi:10.1371/journal.pone.0097485.g006
Figure 7. MMP-8 levels are increased in IPF plasma samples.
Plasma samples were obtained from patients with IPF and healthy
volunteers (control). MMP-8 protein levels were measured using an
ELISA. Data are mean + SEM; n=21 healthy volunteers and n=73
patients with IPF; asterisks indicate p,0.001.
doi:10.1371/journal.pone.0097485.g007
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IPF patients Control subjects
" P value
Number of subjects 73 25
Age (years) 68.7 (7.9)
{ 62.9 (10.4) 0.006
Gender (% male) 69.2 80.0 0.446
Caucasian (%) 96.8 96.0 0.642
Hispanic (%) 3.2 12.0 0.276
FVC (L) 2.65 (0.8) N/A
{{
FVC (% predicted) 69.8 (18.3) N/A
TLC (L) 4.0 (1.1) N/A
TLC (% predicted) 67.5 (21.0) N/A
DLCO (mL/min/mmHg) 13.3 (6.1) N/A
DLCO (% predicted) 49.9 (18.7) N/A
Smoking (pack years) 23.3 (14.1) 2.08 (8.2) ,0.001
{Data shown are mean results (with SD in parentheses) in both groups for age, gender, forced vital capacity (FVC), FVC % predicted (% pred), total lung capacity (TLC),
TLC % predicted, diffusing capacity of the lung for carbon monoxide (DLCO), DLCO % predicted, and smoking pack years.
{{N/A: not available.
"MMP-8 levels were measured in plasma samples from 21 of the 25 control subjects, MMP-8 levels were measured in leukocytes isolated from up to 7 of the 25 control
subjects, and MMP-8 levels were measured in both plasma and leukocyte samples obtained from 3 of the 25 control subjects.
doi:10.1371/journal.pone.0097485.t001
Figure 8. MMP-8 expression is increased in peripheral blood monocytes but not in peripheral blood neutrophils. Neutrophils and
monocytes were isolated from blood samples obtained from IPF patients being evaluated for lung transplantation and healthy volunteers. MMP-8
protein levels were measured in neutrophil lysates (A) and monocyte lysates (C) (all prepared at 5610
6 cells/ml) using an ELISA. In A and C, data are
mean + SEM, n=6–7 healthy volunteers and n=4–22 IPF patients. MMP-8 steady-state mRNA levels were measured in RNA isolated from neutrophils
(B) and monocytes (D) obtained from 7–9 control subjects and 6–9 IPF patients using a commercial gene expression assay for MMP-8 and 18 S as an
endogenous reference. Data are expressed as fold change + SEM in B and as DCT in D (CT for MMP-8 - CT for 18 S as MMP-8 transcripts were not
detected in 7 out of 9 controls [CT .60 for MMP-8 and plotted as DCT .33] or expressed at low levels in monocytes from 2 of the control subjects).
Asterisks indicate p,0.001.
doi:10.1371/journal.pone.0097485.g008
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biomarkers. Although mean plasma MMP-8 levels are .3-fold
higher in IPF patients compared with controls, our results indicate
plasma MMP-8 levels are unlikely to serve as a useful prognostic
biomarker for IPF patients as they do not correlate with rate of
decline in lung function or mortality in IPF patients. Additionally,
plasma MMP-8 levels are not specific for IPF as increased plasma
MMP-8 levels occur in patients with active coronary artery disease
[33] and breast cancer [34]. However, additional studies are
needed to determine whether plasma MMP-8 levels correlate with
other clinical outcomes and parameters in IPF patients including
disease exacerbations.
Blood neutrophil MMP-8 protein and steady state mRNA levels
are similar in IPF patients and control subjects. Until now, it has
been thought that MMP-8 is not synthesized de novo by
circulating mature neutrophils. Rather, MMP-8 is synthesized by
bone marrow precursors of neutrophils and pre-formed MMP-8
protein is stored in neutrophil specific granules and released from
these granules into the extracellular space when the cells
degranulate [35]. However, in the current study, we detected
MMP-8 mRNA transcripts in neutrophils from both IPF patients
and healthy control subjects and this likely reflects the more
sensitive qRT-RT-PCR method used herein when compared with
methods used previously [36]. Membrane-bound MMP-8 on
murine PMNs contributes significantly to MMP-8’s anti-inflam-
matory activities in mice with ALI [12,17]. However, we found no
differences in the expression of membrane-bound MMP-8 on
PMNs from IPF patients versus controls indicating that this form
of the proteinase is unlikely to contribute to lung fibrosis in human
IPF patients.
MMP-8 is not thought to be a monocyte product. However, we
detected MMP-8 mRNA transcripts in monocytes from some
healthy subjects, and MMP-8 gene expression is significantly
increased in monocytes from IPF patients. The reasons for this
finding are not clear, but as MMP-8 gene expression increases in
macrophages activated in vitro, mediators released in IPF lungs
may induce MMP-8 expression in monocytes. Although MMP-8
gene expression is increased in IPF monocytes, we detected similar
low levels of MMP-8 protein in extracts of blood monocyte from
both healthy subjects and IPF patients. Likely, monocytes
synthesize and rapidly release (rather than store) MMP-8 protein.
It is noteworthy that gene expression profiles of PBMCs
(lymphocytes and monocytes) have recently been shown to predict
poor outcomes in IPF patients [32]. However, MMP-8 gene
expression levels in PBMCs do not correlate with mortality in IPF
patients in this publicly-available dataset (personal communica-
tion, Naftali Kaminski, MD). Other studies report that patients
with COPD and sarcoidosis have increased MMP-8 gene
expression in PBMCs [30,31], but we were not able to confirm
these findings when we analyzed other publicly-available micro-
array gene expression datasets of PBMCs from patients with
sarcoidosis or COPD versus healthy control subjects (see Table
S2). However, increased MMP-8 gene expression in blood
monocytes is unlikely to be a predictive or prognostic biomarker
for IPF.
Although BALF levels of MMP-8 have been reported to be
elevated in IPF patients previously [18,20,21], until now the
crucial cellular sources of pro-fibrotic MMP-8 in the lung have not
been identified. We report for the first time that macrophages are
one key cell type contributing to the elevated MMP-8 levels in IPF
lungs, and macrophages in areas of mild as well as severe fibrosis
robustly express MMP-8. While bronchial epithelial cells in
control lungs do not express MMP-8, robust staining for MMP-
8 is detected in bronchial epithelial cells in moderately severe and
severe areas of fibrosis in IPF lungs. MMP-8 is also expressed by
bronchial epithelium and macrophages in patients with bronchi-
ectasis [37]. Thus, under pathologic conditions, mediators released
in the lung may induce MMP-8 expression by bronchial epithelial
cells and lung macrophages. Whether MMP-8 expressed by
bronchial airway epithelium contributes to the fibrotic process in
IPF lungs is not clear. However, MMP-8 expressed by distal
airway epithelium could contribute to epithelial to mesenchymal
transition.
We detected MMP-8 staining in ATII cells in our control lungs,
which has not been reported previously. However, AT II cells
have minimal or no MMP-8 expression in areas of moderately
severe and severe fibrosis in IPF lungs. Although other studies
report that ATII cells have increased apoptosis rates [28,29], our
immunostaining results demonstrate apoptosis in cells other than
ATII cells in IPF lungs (possibly ATI cells). Thus, it is unlikely that
Figure 9. MMP-8 levels in plasma do not correlate with decline in pulmonary function in IPF patients. Serial FVC and DLCO
measurements of lung function were performed on IPF patients being evaluated for lung transplantation. Annual rates of decline in both measures
were calculated as described in Methods and plotted against plasma MMP-8 levels measured using an ELISA. Correlations between MMP-8 plasma
levels and absolute annual rate of decline in FVC (A) or DLCO (B) were calculated using the Spearman Rank Correlation Coefficient; 45 IPF patients
were studied in A and B.
doi:10.1371/journal.pone.0097485.g009
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reduced viability of these cells. While activated murine lung
fibroblasts express MMP-8 [10], we did not detect expression of
MMP-8 by IPF lung fibroblasts. This underscores the importance
of confirming findings obtained in animal models in samples from
humans with the disease.
A recent study reported that MMP-8 protein levels are not
increased in IPF lung tissue when compared with donor lungs that
were not used for lung transplantation as assessed by western
blotting [19]. In contrast, we found that MMP-8 protein levels are
increased in homogenates of lung samples. The reasons for these
different results are not clear but could be related to the status of
the donor lung tissue studied. If the discarded donor lung tissue
was obtained from donors having lung inflammation or injury due
to mechanical ventilation, infection, or other inflammatory
responses in the study of Nkyimbeng et al. [19], this could have
elevated MMP-8 protein levels in the donor lung and contributed
to the lack of a difference in MMP-8 levels between IPF and donor
lungs in this study. It is noteworthy that Nkyimbeng et al. detected
strong positive staining for MMP-8 in alveolar septae of their
control lungs whereas we detected MMP-8 staining only in ATII
cells in control lung sections. In addition, different antibodies were
used in our study versus that of Nkyimbeng et al. which could
recognize different epitopes in MMP-8 leading to differences in the
results if these epitopes undergo different proteolytic processing in
tissues.
MMP-8 promotes lung fibrosis in mice by decreasing lung levels
of MIP-1a and IP-10 [10]. However, in our study, MMP-8 BALF
levels do not correlate indirectly with BALF levels of MIP-1a or
IP-10 in IPF patients, suggesting that these chemokines may not be
MMP-8 substrates and/or MMP-8 has other pro-fibrotic activities
in IPF lungs. Also, measuring levels of MMP-8 and chemokines in
BALF may not reflect proteolytic events occurring in lung
microenvironments other than the alveolar space. It is also
noteworthy that delivering a truncated form of MMP-8 to the
livers of rats with hepatic cirrhosis reduces hepatic fibrosis [38].
Furthermore, MMP-8 has protective anti-inflammatory activities
in mice with acute lung injury [12] and allergen-induced airway
inflammation [39], but pro-inflammatory activities during acute
hepatic injury in mice [40]. Thus, more studies are needed on
human cells and samples to determine whether MMP-8 has pro-
fibrotic or beneficial activities in the human lung.
Our study has some limitations including the relatively small
number of subjects studied. Also, our healthy subjects are modestly
but significantly younger than our IPF patients. MMP-8 levels
increase in tissues in mice as they age [41]. However, our analysis
of MMP-8 plasma levels in older healthy controls ($60 years of
age; n=14) versus younger health controls (,60 years of age;
n=11) revealed similar median MMP-8 plasma levels (364 vs.
645 pg/ml, respectively; p=0.119). Thus, it is unlikely that the
higher MMP-8 plasma levels in IPF patients are due to their
greater age, but this needs to be confirmed in future studies.
Most of our IPF patients have a history of smoking cigarettes
while most of our control subjects are non-smokers. Smoking
status could affect MMP-8 levels in blood and lung samples as
human PMNs incubated with cigarette smoke extract release
increased amounts of MMP-8 and MMP-9 [42]. Additionally,
plasma MMP-8 levels correlate with smoking status [43].
Therefore, the greater cigarette smoking history in our IPF cohort
compared with that in our control subjects could potentially
contribute to the higher plasma MMP-8 levels observed in the IPF
patients.
In conclusion, we confirm that MMP-8 levels are robustly
increased in plasma samples from IPF patients. However, we
report for the first time that MMP-8 plasma levels do not correlate
with mortality or decline in lung function in IPF patients. We
identify novel cellular culprits expressing increased levels of MMP-
8 in IPF patients (blood monocytes, lung macrophages, and
bronchial epithelial cells). We also provide new insights into the
form of MMP-8 that is increased in IPF lungs (active MMP-8).
Additional studies are needed to determine whether plasma MMP-
8 levels correlate with other clinical parameters not studied herein.
If MMP-8 is found to have pro-fibrotic activities in human as well
as murine lungs, our results may help guide future studies testing
the efficacy of novel therapies targeting MMP-8 in halting the
progression of lung fibrosis in IPF patients.
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